DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Kilitch Drugs (India) Limited — Outcome of Board Meeting

NSE 54 min ago·13 Aug 2026, 3:26 pm

Kilitch Drugs India

Kilitch Drugs (India) Limited has informed the stock exchange about its financial results for the period ending June 30, 2026. The company has submitted these details to ensure transparency and compliance with market regulations.

This disclosure is a routine update for investors, providing visibility into the company's financial performance over the specified quarter. For retail investors, keeping track of such periodic filings helps in understanding the company's operational progress and financial health.

Investors should look for key metrics such as revenue growth, profit margins, and any commentary from the management regarding future outlook. Monitoring these updates will help in assessing the company's trajectory and making informed investment decisions.